Exactly! Merck is bracing for quite a hit in 2028- between 25 billion patent cliff for Keytruda AND the 8.9 billion cliff that same year for Gardasil 9, there will be significant impact to the company. And I’m not sure that we have any real blockbusters in the clinical. I don’t think there’s any other pharma company facing anything close to us in the next decade. They are staggering numbers. This, coupled by lower than expected growth for Gardasil in China (reflected in stock slump)… it’s no wonder that the bean counters are nervous!